Navigation Links
Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies

Two researchers from the University Hospital and the Center for Applied Medical Research (CIMA) from the University of Navarra have published an article in Nature Cancer Reviews, one of the leading scientific journals in the area of cancer studies. The article, written by Ignacio Melero and Sandra Hervas-Stubbs, together with other scientists from the United States and Great Britain, addresses the use of a new pharmaceutical family with practical applications in cancer and chronic viral illnesses.

Specifically, the article discusses using monoclonal antibodies in order to stimulate the immune system. In this therapy the antibodies are directed to the immune system cells in order to provoke a stronger reaction against cancer. This has the advantage of exploiting a mechanism with an action distinct from the other strategies currently being used to treat cancer, and is capable of interacting with the current treatments so as to make both forms of treatment more powerful.

Currently this treatment is being tested in patients with melanoma, kidney and ovarian cancer because there are more ways of measuring the response of the immune system, but he expects to be able to expand this to include other forms of cancer.

Five cancer-fighting agents being tested

The first cancer-fighting agent of this kind, anti-CTLA-4, began to be tested in patients in 1999. In melanoma treatment, between 15 and 20% of clinical objectives have been reached (reduction or disappearance of the tumor), which the researchers see as a positive sign to continue with the research.

Currently, the researchers study its benefits in cancer survivors through two clinical tests in the third phase. In two years we will test its use as the sole means of treatment, and we will need more time in order to know if its effects in treatment combinations are as positive as the results on test animals predict.

Aside from this, there are another f our members of this monoclonal antibiotic family, which stimulate the immune system, currently being developed. Their use in patients began a year and a half ago, and to date no conclusions as to their effectiveness has been published.


'"/>

Source:Elhuyar Fundazioa


Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... July 20, 2017 , ... Resoundant, Inc. is ... imaging centers around the U.S. that offer MR Elastography for liver fibrosis staging. ... needle biopsy for staging liver fibrosis assessment. , “MRE:connect was created in response ...
(Date:7/20/2017)... 2017   KCNQ2 Cure Alliance  and ... today announced that they have completed the first ... implicated in KCNQ2 epileptic encephalopathy. They also report ... case involving an additional KCNQ2 genetic mutation. ... Pairnomix entered into a collaboration to further explore ...
(Date:7/18/2017)... ... July 18, 2017 , ... Genedata, a leading provider of ... technology company, has implemented Genedata Biologics ™ to scale-up their bispecific antibody ... and Neurodegenerative Diseases. , The need to systematically evaluate large panels of ...
(Date:7/17/2017)... ... July 17, 2017 , ... Whitehouse Laboratories is ... to encompass the full series of ISO 80369 standard test procedures. The ISO ... device and drug delivery systems. With this recent expansion, Whitehouse Labs becomes one ...
Breaking Biology Technology: